PharmaSGP (PSG) Q1 2025 earnings summary

Executive summary

• Revenue grew 10.8% year-over-year to €33.5 million in Q1 2025, with strong performance in Germany and Italy.

• Adjusted EBITDA increased 4.0% to €9.2 million, though margin declined to 27.5% from 29.4% due to higher COGS.

• Profit for the period rose to €4.73 million, up from €4.56 million in Q1 2024.

• Health Brands drove growth (+12.8%), while Beauty Brands declined 36.7% year-over-year.

Financial highlights

• EBIT reached €6.84 million, up from €6.33 million year-over-year.

• Basic and diluted EPS increased to €0.41 from €0.38.

• Cash and cash equivalents rose 10.7% to €29.3 million as of March 31, 2025.

• Equity increased 14.7% to €36.7 million, mainly from profit for the period.

• Net cash flows from operating activities decreased to €4.2 million from €6.9 million year-over-year.

Outlook and guidance

• OTC market in Germany expected to grow at 2.6% CAGR through 2029; European OTC market at 3.7%.

• PharmaSGP anticipates continued growth in core Health Brands and further expansion in European markets.